Study guide
3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
Key Takeaways Explain This Topic AI
Dihydropyrimidine dehydrogenase (DPYD) inactivates >80% of 5-fluorouracil (5-FU) and capecitabine; CPIC guidelines mandate calculating the Gene Activity Score (AS) to execute a 50% starting dose reduction for Intermediate Metabolizers (AS 1.0–1.5) and avoidance or ≥75% dose reduction with PK monitoring for Poor Metabolizers (AS 0–0.5) to prevent fatal myelosuppression and mucositis.
Uridine triacetate (Vistogard) is the specific FDA-approved emergency antidote for fluoropyrimidine toxicity or life-threatening overdose; it competitively blocks cytotoxic fluorouridine triphosphate (FUTP) incorporation into host cellular RNA and must be administered within 96 hours of fluoropyrimidine termination.
TPMT and NUDT15 mediate the inactivation and detoxification of thiopurines (6-mercaptopurine, 6-thioguanine, azathioprine); while TPMT deficiency is prevalent in European/African lineages, NUDT15 variants (*3) predominate in East Asian and Hispanic populations, with homozygous deficient individuals requiring ~90% dose reductions to avert catastrophic bone marrow aplasia.
UGT1A1 glucuronidates the active irinotecan topoisomerase I inhibitor metabolite SN-38 into inactive SN-38G; homozygosity for the UGT1A1 28 promoter polymorphism ((TA)7/(TA)7) or UGT1A1 6 reduces glucuronidation, markedly increasing the incidence of life-threatening Grade 4 neutropenia and severe delayed diarrhea.
CYP2D6 bioactivates the prodrug tamoxifen into its active metabolite endoxifen (exhibiting ~100-fold higher affinity for estrogen receptors); CYP2D6 Poor Metabolizers or patients co-prescribed potent CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) exhibit subtherapeutic endoxifen concentrations, requiring transition to aromatase inhibitors or non-inhibiting antidepressants (venlafaxine).
Last updated: August 2026
Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
Pharmacogenomics (PGx) evaluates how inherited constitutional genetic variations alter drug absorption, distribution, metabolism, excretion, and target sensitivity. In oncology, where antineoplastic agents possess exceptionally narrow therapeutic indices and life-threatening toxicities, preemptive pharmacogenomic testing and phenotype-directed dose individualization prevent fatal adverse drug reactions while maximizing therapeutic efficacy.
The Board Certified Oncology Pharmacist (BCOP) plays a leadership role in translating guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , the Dutch Pharmacogenetics Working Group (DPWG) , and the FDA into clinical order verification pathways and institutional decision-support rules.
1. DPYD and Fluoropyrimidines (5-FU, Capecitabine)
Fluoropyrimidines—including intravenous 5-fluorouracil (5-FU) and its oral carbamate prodrug capecitabine—form the cytotoxic backbone for gastrointestinal, breast, and head and neck malignancies. +---------------------------------------------------------------------------------------------------+
- | 5-FLUOROURACIL (5-FU) METABOLISM & DPYD CLEARANCE |
- | |
- | [ADMINISTERED 5-FU / CAPECITABINE] |
- | | |
- | +--------------------------+--------------------------+ |
- | | (>80% - 85% OF DOSE) | (~15% - 20% OF DOSE) |
- | v v |
- | [DPYD ENZYMATIC CATABOLISM] [ANABOLIC ACTIVATION] |
- | * Dihydropyrimidine Dehydrogenase (Rate-Limiting) * Converted via intracellular kinases|
- | * 5-FU ---> DHFU (Dihydrofluorouracil) * Forms: |
- | * DHFU ---> Inactive Fluoro-beta-alanine (FBAL) 1. FdUMP (Inhibits Thymidylate |
- | * Excreted safely in urine Synthase -> Blocks DNA Synth) |
- | 2. FUTP (Misincorporated into RNA)|
- | 3. FdUTP (Misincorporated into DNA)|
- | |
- | [DPYD DEFICIENCY CATASTROPHE] |
- | DPYD Inactivation Impaired ---> Massive Accumulation of Active Anabolites (FdUMP/FUTP) |
- | ---> Fatal Pancytopenia, Denuding Enteritis, Intractable Diarrhea, Toxic Encephalopathy |
- +---------------------------------------------------------------------------------------------------+
- Clinical Pharmacogenetics: DPYD Activity Score System
To standardize genotype-to-phenotype translation, CPIC established a standardized DPYD Gene Activity Score (AS) calculated by summing the functional activity scores assigned to each of the patient's two inherited DPYD alleles. +---------------------------------------------------------------------------------------------------+
- | DPYD ACTIVITY SCORE CALCULATION |
- | |
- | [ALLELE FUNCTIONALITY ASSIGNMENTS] |
- | * Normal Function (Activity Value = 1.0): |
- | - DPYD*1 (Wild-Type reference) |
- | * Decreased Function (Activity Value = 0.5): |
- | - c.2846A>T (p.Asp949Val, rs67376798) |
- | - c.1129-5923C>G (HapB3 / c.1236G>A, rs56038477 / rs75017182) |
- | * No Function / Null Alleles (Activity Value = 0.0): |
- | - DPYD*2A (c.1905+1G>A, IVS14+1G>A splice site, rs3918290) |
- | - DPYD*13 (c.1679T>G, p.Ile560Ser, rs55886062) |
- | - c.2194G>A (p.Glu732Lys) |
- | |
- | TOTAL DPYD ACTIVITY SCORE = (Score of Allele 1) + (Score of Allele 2) |
- +---------------------------------------------------------------------------------------------------+
- CPIC DPYD Dosing Guidelines
Phenotype Total Activity Score (AS) Genotype Examples CPIC Therapeutic Recommendation & Dose Adjustment
Normal Metabolizer (NM) 2.0 *1/*1 100% standard starting dose. Initiate normal weight/BSA-based dosing.
Intermediate Metabolizer (IM) 1.0 or 1.5 *1/*2A (AS 1.0); *1/*13 (AS 1.0); *1/c.2846A>T (AS 1.5); *1/HapB3 (AS 1.5) Reduce starting dose by 50% (for AS 1.0) or 25%–50% (for AS 1.5). Titrate upward in subsequent cycles based on clinical tolerability and therapeutic drug monitoring (TDM).
Poor Metabolizer (PM) 0.0 or 0.5 *2A/*2A (AS 0.0); *2A/*13 (AS 0.0); *2A/HapB3 (AS 0.5) Strongly avoid 5-FU and capecitabine. Use alternative non-fluoropyrimidine regimens. If fluoropyrimidine is clinically mandatory in AS 0.5, reduce starting dose by ≥75%–80% with PK monitoring.
2. Fluoropyrimidine Toxicity Rescue: Uridine Triacetate
When a patient experiences life-threatening early-onset fluoropyrimidine toxicity (regardless of known DPYD genotype) or receives an accidental overdose (e.g., infusion pump runaway delivering a 46-hour 5-FU bag in 4 hours), immediate administration of uridine triacetate (Vistogard) is life-saving. +---------------------------------------------------------------------------------------------------+
- | URIDINE TRIACETATE (VISTOGARD) RESCUE MECHANISM |
- | |
- | [ORAL URIDINE TRIACETATE] ---> Rapidly deacetylated in gut/liver to free URIDINE |
- | | |
- | v |
- | [SYSTEMIC URIDINE SURGE] ---> Competes with toxic fluorouridine triphosphate (FUTP) |
- | | |
- | v |
- | [MOLECULAR COMPETITION] ---> Satures Host RNA Polymerase & Host Cellular UTP Pools |
- | * Prevents FUTP misincorporation into host gastrointestinal |
- | and hematopoietic stem cell RNA |
- | * Halts enterocyte destruction and bone marrow aplasia |
- +---------------------------------------------------------------------------------------------------+
Clinical Administration Parameters:
Dosage: 10 grams orally every 6 hours for 20 doses (pediatric: 6.2 g/m2 every 6 hours).
Timing: Must be initiated within 96 hours of the end of fluoropyrimidine administration.
Preparation: Mix 10 g packet with 3 to 4 ounces of soft food (applesauce, pudding, yogurt) and ingest immediately without chewing the granules; can be administered via NG/G-tube.
3. TPMT and NUDT15: Thiopurine S-Methyltransferase & Nudix Hydrolase 15
Thiopurines—including 6-mercaptopurine (6-MP) in acute lymphoblastic leukemia (ALL), 6-thioguanine (6-TG) in AML, and azathioprine (AZA) in non-malignant immunosuppression—are antimetabolite prodrugs converted via hypoxanthine-guanine phosphoribosyltransferase (HPRT) into cytotoxic thioguanine nucleotides (TGNs: TGTP and TdGTP) that misincorporate into DNA and RNA. +---------------------------------------------------------------------------------------------------+
- | DUAL THIOPURINE DETOXIFICATION: TPMT & NUDT15 |
- | |
- | [6-MERCAPTOPURINE] |
- | | |
- | +----------------------------+----------------------------+ |
- | | | |
- | v v |
- | [TPMT INACTIVATION PATHWAY] [HPRT CYTOTOXIC PATHWAY] |
- | * Thiopurine S-methyltransferase * Forms ThiodGMP ---> Thio-dGTP |
- | * Converts 6-MP ---> 6-Methyl-MP (inactive) * Misincorporates into DNA |
- | * DEFICIENCY: Shunts 100% into Cytotoxic TGNs! | |
- | v |
- | [NUDT15 SANITIZING PATHWAY] |
- | * Nudix Hydrolase 15 |
- | * Hydrolyzes Thio-dGTP ---> Thio-dGMP|
- | * Cleans nucleotide pool |
- | * DEFICIENCY: Uncontrolled DNA |
- | Misincorporation & Fatal Aplasia |
- +---------------------------------------------------------------------------------------------------+
- Ancestral Distribution and Testing Mandates
TPMT Variants (*2, *3A, *3B, *3C): Account for >90% of inactivating alleles in populations of European and African descent. TPMT 3A (carrying two missense variants, c.460G>A and c.719A>G) is the most common deficient allele in Caucasians.
* NUDT15 Variants ( 3, e.g., p.Arg139Cys, rs116855232): Highly prevalent in individuals of East Asian (9.8% allele frequency) and Hispanic/Native American ancestries , while rare in Caucasians (<0.2%).
CPIC Thiopurine (6-MP) Dosing Matrix
TPMT Phenotype NUDT15 Phenotype Starting Dose Recommendation (6-MP) Titration Strategy
Normal (NM) Normal (NM) 100% standard starting dose (e.g., 75 mg/m2/day) Titrate based on ANC and disease protocol.
Intermediate (IM) Normal (NM) Reduce to 30%–80% of starting dose (e.g., 25–50 mg/m2/day) Titrate slowly every 2–4 weeks based on myelosuppression.
Normal (NM) Intermediate (IM) Reduce to 30%–80% of starting dose (e.g., 25–50 mg/m2/day) Titrate slowly every 2–4 weeks based on myelosuppression.
Intermediate (IM) Intermediate (IM) Reduce to 20%–50% of starting dose (e.g., 15–35 mg/m2/day) Extreme caution; monitor ANC weekly.
Poor (PM) Any Phenotype Reduce dose by ~90% (administer 10% of standard dose) Dose 6-MP 3 times weekly instead of daily; monitor TGN levels.
Any Phenotype Poor (PM) Reduce dose by ~90% (administer 10% of standard dose) Dose 6-MP 3 times weekly instead of daily; monitor TGN levels.
4. UGT1A1 and Irinotecan Toxicity
Irinotecan (CPT-11) is a topoisomerase I inhibitor prodrug converted by tissue carboxylesterases (CES1/CES2) into its active metabolite SN-38 , which exhibits 1,000-fold greater topoisomerase inhibitory potency than parent irinotecan. SN-38 is cleared exclusively via hepatic glucuronidation mediated by UDP-glucuronosyltransferase 1A1 (UGT1A1) to form inactive SN-38 glucuronide ( SN-38G ). +---------------------------------------------------------------------------------------------------+
- | IRINOTECAN / SN-38 METABOLISM & UGT1A1 INACTIVATION |
- | |
- | [IRINOTECAN (CPT-11)] |
- | | |
- | v (Carboxylesterase CES1 / CES2) |
- | [ACTIVE SN-38 METABOLITE] |
- | (Potent Topoisomerase I Poison: GI/Bone Marrow) |
- | | |
- | v (Hepatic UGT1A1 Glucuronidation) |
- | [INACTIVE SN-38G GLUCURONIDE] |
- | | |
- | v |
- | [Biliary & Fecal Elimination] |
- | |
- | [UGT1A1*28 /*28 (TA)7/(TA)7 IMPAIRMENT] |
- | Defective Glucuronidation ---> Prolonged Systemic Exposure to Toxic SN-38 |
- | ---> Grade 4 Neutropenia & Severe Delayed Diarrhea (Secretory Enterocyte Apoptosis) |
- +---------------------------------------------------------------------------------------------------+
- Polymorphisms and Dosing Strategy
UGT1A1 28 (rs8100241): An extra TA dinucleotide repeat in the TATA box promoter region: ( T A ) 7 (TA)_7 ( T A ) 7 instead of the wild-type ( T A ) 6 (TA)_6 ( T A ) 6 (*1). Homozygous ( T A ) 7 / ( T A ) 7 (TA)_7/(TA)_7 ( T A ) 7 / ( T A ) 7 (*28/*28) is the molecular basis of Gilbert syndrome and reduces UGT1A1 transcription by ~70%.
UGT1A1 6 (c.211G>A, p.Gly71Arg): Highly prevalent in Asian populations (allele frequency ~15%–20%), causing similar impairment in SN-38 glucuronidation.
Clinical Actionability:
High-Dose Irinotecan (>250 mg/m2 every 3 weeks): FDA package insert and guidelines recommend a mandatory at least one dose level reduction (e.g., 20%–25%) in homozygous *28/*28 patients.
Standard-Dose Irinotecan (150–180 mg/m2 in FOLFIRI / FOLFIRINOX): Can be initiated at standard dose with close clinical monitoring for neutropenia and delayed diarrhea, or reduced by one dose level if clinically frail.
5. CYP2D6 and Tamoxifen Bioactivation
Tamoxifen is a Selective Estrogen Receptor Modulator (SERM) and the cornerstone of endocrine therapy for premenopausal hormone receptor-positive breast cancer. Tamoxifen itself is a weak prodrug with low binding affinity for the estrogen receptor. +---------------------------------------------------------------------------------------------------+
- | TAMOXIFEN BIOACTIVATION CASCADE TO ENDOXIFEN |
- | |
- | [TAMOXIFEN PRODRUG] |
- | (Low Affinity for ER) |
- | | |
- | +-------------------------------+-------------------------------+ |
- | | (~90% OF METABOLISM) | (~10% OF DOSE) |
- | v (CYP3A4 / CYP3A5) v (CYP2D6) |
- | [N-Desmethyltamoxifen] [4-Hydroxytamoxifen] |
- | | | (100x ER Bind) |
- | v (CYP2D6 - CRITICAL RATE LIMITING STEP!) v (CYP3A4) |
- | +-------------------------------+-------------------------------+ |
- | | |
- | v |
- | [4-OH-N-DESMETHYLTAMOXIFEN] |
- | (ENDOXIFEN) |
- | * 30- to 100-fold higher affinity for ER |
- | * Primary driver of clinical anti-tumor efficacy |
- +---------------------------------------------------------------------------------------------------+
- Phenotypes and Drug-Drug Interactions
CYP2D6 Phenotype Activity Score Endoxifen Concentration CPIC Clinical Recommendation
Ultrarapid (UM) >2.25 Normal to elevated Initiate standard tamoxifen 20 mg PO daily.
Normal (NM) 1.25–2.25 High/therapeutic Initiate standard tamoxifen 20 mg PO daily.
Intermediate (IM) 0.25–1.0 Suboptimal/moderate Consider dose escalation to 40 mg daily OR switch to Aromatase Inhibitor (if postmenopausal).
Poor Metabolizer (PM) 0.0 (*3, *4, *5, *6) Subtherapeutic (profoundly reduced) Strongly recommend alternative endocrine therapy: Switch to Aromatase Inhibitor (AI) (+ GnRH agonist if premenopausal) due to higher risk of breast cancer recurrence.
[!CRITICAL] Avoid Potent CYP2D6 Inhibiting Antidepressants: Co-prescribing strong CYP2D6 inhibitors with tamoxifen phenocopies a Poor Metabolizer state, dropping endoxifen to subtherapeutic levels.
CONTRAINDICATED / AVOID: Fluoxetine, Paroxetine, Bupropion.
PREFERRED ALTERNATIVES FOR HOT FLASHES / DEPRESSION: Venlafaxine (SNRI), Desvenlafaxine, Citalopram, Escitalopram, or Gabapentin.
6. Ancillary Pharmacogenomic Biomarkers in Supportive Care
Gene / Allele Drug Interaction Clinical Risk Actionable Recommendation
G6PD Deficiency Rasburicase (Recombinant urate oxidase) Severe, life-threatening hemolysis and methemoglobinemia (hydrogen peroxide generation from uric acid breakdown overwhelms glutathione-deficient RBCs). Contraindicated. Screen patients of high-risk ancestry (African, Mediterranean, Middle Eastern, Southeast Asian) prior to rasburicase; use allopurinol if deficient.
CYP2C19 Voriconazole (Antifungal prophylaxis/therapy) CYP2C19 Poor Metabolizers (*2, *3) exhibit 4-fold higher voriconazole AUC -> severe neurotoxicity/visual hallucinations; Ultrarapid (*17) exhibit subtherapeutic failure. Perform TDM (trough target 1.5–5.0 mcg/mL) or select posaconazole / isavuconazole in known PM or UM phenotypes.
HLA-B*57:01 Abacavir (Antiretroviral in oncology patients with HIV) Severe, fatal multi-organ hypersensitivity reaction. Mandatory screening; avoid if positive.
HLA-B 15:02 / HLA-A 31:01 Carbamazepine (Neuropathic pain) Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Pre-therapeutic screening in Asian populations (*15:02) and broad populations (*31:01).